person

Jens Jakob T.

Country
Denmark
Department
Department of Cardiology

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
52
Sites with multiple studies

Has run more than one trial at 52 of 78 partner sites.

Specializations

Hypertrophic Cardiomyopathy Research

The investigator specializes in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM), conducting research on innovative therapeutic approaches. Their work encompasses the evaluation of novel treatments including aficamten and mavacamten for patients with symptomatic HCM.

  • Obstructive HCM management
  • Non-obstructive HCM therapeutics
  • Long-term safety assessment

The investigator focuses on evaluating exercise capacity and cardiac structure improvements in HCM patients.

Acute Heart Failure Studies

The investigator conducts research in acute heart failure treatment, particularly focusing on managing pulmonary congestion. Their work examines various therapeutic strategies including vasodilation and loop-diuretics in emergency settings.

  • Pulmonary edema management
  • Emergency treatment protocols
  • Combination therapy approaches

The research emphasizes early intervention strategies within the first hours of hospital admission.

Chronic Heart Failure Management

The investigator studies chronic heart failure treatment with a particular focus on aldosterone antagonist therapy. Their research compares the efficacy of different treatment options for patients with reduced ejection fraction.

  • Mortality risk assessment
  • Comparative medication studies
  • Heart failure clinic outcomes

The research aims to optimize treatment strategies for heart failure patients under clinical care.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.